HR Execs on the Move

Genocea

www.genocea.com

 
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.genocea.com
  • 100 Acorn Park Drive
    Cambridge, MA USA 02140
  • Phone: 617.876.8191

Executives

Name Title Contact Details

Similar Companies

Hepion Pharmaceuticals

Hepion Pharmaceuticals is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. T

MBX Biosciences

MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.

Elevian

Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.

Transgene

Transgene SA is a France-based fully integrated biopharmaceutical company specialising in immunotherapeutics to treat cancer and infectious diseases. The company has subsidiaries in China and in the USA.

Khiron

Khiron Life Sciences Corp. is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. With a focused regional strategy and patient oriented approach, the company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people.